Travis Taylor, MD
Cardiovascular Disease · Corpus Christi, TXNPI 1386969343
Payments from drug & device makers
Across 392 payments — averaging $1723.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$491K
- AstraZeneca$171K
- Abbott$5K
- Medtronic$3K
- Boston Scientific$1K
- Johnson & Johnson$972
- plus $4K from 24 others
Across 2 payments — averaging $9759.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$20K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 7 | $490,672 |
| AstraZeneca | 20 | $171,199 |
| Abbott | 73 | $5,205 |
| Medtronic(2 entities) | 95 | $2,521 |
| Boston Scientific | 9 | $1,248 |
| Johnson & Johnson | 51 | $972 |
| Philips North America LLC | 8 | $764 |
| Abiomed | 16 | $682 |
| Pfizer | 25 | $362 |
| Novartis | 16 | $362 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $226 |
| Terumo Medical Corporation | 2 | $185 |
| E.r. Squibb & Sons, L.L.C. | 9 | $159 |
| Actelion Pharmaceuticals US, Inc. | 2 | $157 |
| Esperion Therapeutics, Inc. | 6 | $155 |
| Amgen | 8 | $130 |
| Merck | 8 | $126 |
| W. L. Gore & Associates, Inc. | 4 | $113 |
| Celonova Biosciences, Inc. | 1 | $98 |
| Boehringer Ingelheim | 4 | $72 |
| Recor Medical Inc | 1 | $70 |
| Cardiovascular Systems Inc. | 3 | $54 |
| Cvrx, Inc. | 3 | $54 |
| Edwards Lifesciences | 3 | $45 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Shockwave Medical, Inc | 1 | $25 |
| Irhythm Technologies, Inc. | 1 | $22 |
| Biotronik Inc. | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$675,749 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Corpus Christi
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.